Current and emerging treatment options for Wiskott-Aldrich syndrome

Expert Review of Clinical Immunology

Volumn 11, Issue 9, 2015, Pages 1015-1032

  Worth, Austen Jj ^a   Thrasher, Adrian J ^b  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Allogeneic hematopoietic stem cell transplantation; autoimmunity; gene therapy; primary immunodeficiency; thrombocytopenia; Wiskott Aldrich syndrome; Wiskott Aldrich syndrome protein; X linked thrombocytopenia

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; AZITHROMYCIN; BORTEZOMIB; BUSULFAN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; IBRUTINIB; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LENTIVIRUS VECTOR; POLYSACCHARIDE VACCINE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETROVIRUS VECTOR; RITUXIMAB; SULFAMETHOXAZOLE; TACROLIMUS; THYMOCYTE ANTIBODY; TRANEXAMIC ACID; TREOSULFAN; TRIMETHOPRIM; WISKOTT ALDRICH SYNDROME PROTEIN; WAS PROTEIN, HUMAN;

ANTIBIOTIC THERAPY; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; ECZEMA; FOLLOW UP; GAIN OF FUNCTION MUTATION; GENE THERAPY; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE FUNCTION TEST; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; INFLAMMATORY BOWEL DISEASE; LONG TERM CARE; MISSENSE MUTATION; MORBIDITY; MORTALITY; MYCOSIS; MYELOABLATIVE CONDITIONING; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; ORGAN DONOR; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRENATAL DIAGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SCORING SYSTEM; SPLENECTOMY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT INDICATION; VASCULITIS; VIRAL GENE THERAPY; WAS CLINICAL SCORE; WHOLE BODY RADIATION; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER; GENETIC PREDISPOSITION; GENETICS; INFANT; MUTATION; PRESCHOOL CHILD; PROCEDURES; SURVIVAL ANALYSIS; WISKOTT-ALDRICH SYNDROME;

CHILD, PRESCHOOL; GENETIC PREDISPOSITION TO DISEASE; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MUTATION; SURVIVAL ANALYSIS; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 84939604953     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1062366     Document Type: Review

References (138)

1. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994; 78: 635-44
2. Stray-Pedersen A, Abrahamsen TG, Froland SS. Primary immunodeficiency diseases in Norway. J Clin Immunol 2000; 20: 477-85
3. Perry GS III, Spector BD, Schuman LM, et al. The wiskott-aldrich syndrome in the United States and Canada (1892-1979). J Pediatr 1980; 97: 72-8
4. Mahlaoui N, Pellier I, Mignot C, et al. Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome. Blood 2013; 121: 1510-16
5. Blundell MP, Worth A, Bouma G, Thrasher AJ. The Wiskott-Aldrich syndrome: The actin cytoskeleton and immune cell function. Dis Markers 2010; 29: 157-75
6. Catucci M, Castiello MC, Pala F, et al. Autoimmunity in Wiskott-Aldrich syndrome: an unsolved enigma. Front Immunol 2012; 3: 209
7. Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome: a comprehensive review. Ann N Y Acad Sci 2013; 1285: 26-43
8. Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol 2010; 10: 182-92
9. Cleland SY, Siegel RM. Wiskott-Aldrich Syndrome at the nexus of autoimmune and primary immunodeficiency diseases. FEBS Lett 2011; 585: 3710-14
10. Kreishman-Deitrick M, Goley ED, Burdine L, et al. NMR analyses of the activation of the Arp2/3 complex by neuronal Wiskott-Aldrich syndrome protein. Biochemistry 2005; 44: 15247-56
11. Panchal SC, Kaiser DA, Torres E, et al. A conserved amphipathic helix in WASP/Scar proteins is essential for activation of Arp2/3 complex. Nat Struct Biol 2003; 10: 591-8
12. Kim AS, Kakalis LT, Abdul-Manan N, et al. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 2000; 404: 151-8
13. Lim RP, Misra A, Wu Z, Thanabalu T. Analysis of conformational changes in WASP using a split YFP. Biochem Biophys Res Commun 2007; 362: 1085-9
14. Martinez-Quiles N, Rohatgi R, Anton IM, et al. WIP regulates N-WASP-mediated actin polymerization and filopodium formation. Nat Cell Biol 2001; 3: 484-91
15. Chou HC, Anton IM, Holt MR, et al. WIP regulates the stability and localization of WASP to podosomes in migrating dendritic cells. Curr Biol 2006; 16: 2337-44
16. de la Fuente MA, Sasahara Y, Calamito M, et al. WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc Nat Acad Sci 2007; 104: 926-31
17. Sasahara Y, Rachid R, Byrne MJ, et al. Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol Cell 2002; 10: 1269-81
18. Tsuboi S, Meerloo J. Wiskott-Aldrich syndrome protein is a key regulator of the phagocytic cup formation in macrophages. J Biol Chem 2007; 282: 34194-203
19. Blanchoin L, Amann KJ, Higgs HN, et al. Direct observation of dendritic actin filament networks nucleated by Arp2/3 complex and WASP/Scar proteins. Nature 2000; 404: 1007-11
20. Badour K, Zhang J, Shi F, et al. Fyn and PTP-PEST-mediated regulation of Wiskott-Aldrich syndrome protein (WASp) tyrosine phosphorylation is required for coupling T cell antigen receptor engagement to WASp effector function and T cell activation. J Exp Med 2004; 199: 99-112
21. Cory GO, Garg R, Cramer R, Ridley AJ. Phosphorylation of tyrosine 291 enhances the ability of WASp to stimulate actin polymerization and filopodium formation. Wiskott-Aldrich Syndrome protein. J Biol Chem 2002; 277: 45115-21
22. Kato M, Miki H, Imai K, et al. Wiskott-Aldrich syndrome protein induces actin clustering without direct binding to Cdc42. J Biol Chem 1999; 274: 27225-30
23. Cory GO, Cramer R, Blanchoin L, Ridley AJ. Phosphorylation of the WASP-VCA domain increases its affinity for the Arp2/3 complex and enhances actin polymerization by WASP. Mol Cell 2003; 11: 1229-39
24. Torres E, Rosen MK. Contingent phosphorylation/dephosphorylation provides a mechanism of molecular memory in WASP. Mol Cell 2003; 11: 1215-27
25. Blundell MP, Bouma G, Metelo J, et al. Phosphorylation of WASp is a key regulator of activity and stability in vivo. Proc Natl Acad Sci USA 2009; 106: 15738-43
26. Reicher B, Joseph N, David A, et al. Ubiquitylation-dependent negative regulation of WASp is essential for actin-cytoskeleton dynamics. Mol Cell Biol 2012; 32 (15): 3153-63
27. Watanabe Y, Sasahara Y, Ramesh N, et al. T-cell receptor ligation causes Wiskott-Aldrich syndrome protein degradation and F-actin assembly downregulation. J Allergy Clin Immunol 2013; 132: 648-55
28. Parolini O, Berardelli S, Riedl E, et al. Expression of Wiskott-Aldrich syndrome protein (WASP) gene during hematopoietic differentiation. Blood 1997; 90: 70-5
29. Snapper SB, Takeshima F, Anton I, et al. N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility. Nat Cell Biol 2001; 3: 897-904
30. Cotta-de-Almeida V, Westerberg L, Maillard MH, et al. Wiskott Aldrich syndrome protein (WASP) and N-WASP are critical for T cell development. Proc Natl Acad Sci USA 2007; 104: 15424-9
31. Sadhukhan S, Sarkar K, Taylor M, et al. Nuclear role of WASp in gene transcription is uncoupled from its ARP2/3-dependent cytoplasmic role in actin polymerization. J Immunol 2014; 193: 150-60
32. Looi CY, Sasahara Y, Watanabe Y, et al. The open conformation of WASP regulates its nuclear localization and gene transcription in myeloid cells. Int Immunol 2014; 26: 341-52
33. Taylor MD, Sadhukhan S, Kottangada P, et al. Nuclear role of WASp in the pathogenesis of dysregulated TH1 immunity in human Wiskott-Aldrich syndrome. Sci Transl Med 2010; 2: 37ra44
34. Abinun M, Mikuska M, Filipovic B. Infantile cortical hyperostosis associated with the Wiskott-Aldrich syndrome. Eur J Pediatr 1988; 147: 518-19
35. Adriani M, Jones KA, Uchiyama T, et al. Defective inhibition of B-cell proliferation by Wiskott-Aldrich syndrome protein-deficient regulatory T cells. Blood 2011; 117: 6608-11
36. Marangoni F, Trifari S, Scaramuzza S, et al. WASP regulates suppressor activity of human and murine CD4+CD25+FOXP3+ natural regulatory T cells. J Experim Med 2007; 204: 369-80
37. Park JY, Shcherbina A, Rosen FS, et al. Phenotypic perturbation of B cells in the Wiskott-Aldrich syndrome. Clin Exp Immunol 2005; 139: 297-305
38. Recher M, Burns SO, de la Fuente MA, et al. B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood 2012; 119: 2819-28
39. Westerberg LS, de la Fuente MA, Wermeling F, et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood 2008; 112: 4139-47
40. Simon KL, Anderson SM, Garabedian EK, et al. Molecular and phenotypic abnormalities of B lymphocytes in patients with Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2014; 133: 896-9
41. Castiello MC, Bosticardo M, Pala F, et al. Wiskott-Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans. J Autoimmun 2014; 50: 42-50
42. Becker-Herman S, Meyer-Bahlburg A, Schwartz MA, et al. WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med 2011; 208: 2033-42
43. Schurman SH, Candotti F. Autoimmunity in Wiskott-Aldrich syndrome. Curr Opin Rheumatol 2003; 15: 446-53
44. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994; 125: 876-85
45. Mantadakis E, Sawalle-Belohradsky J, Tzanoudaki M, et al. X-linked thrombocytopenia in three males with normal sized platelets due to novel WAS gene mutations. Pediatr Blood Cancer 2014; 61: 2305-6
46. Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004; 103: 456-64
47. Lutskiy MI, Rosen FS, Remold-ODonnell E. Genotype-proteotype linkage in the Wiskott-Aldrich syndrome. J Immunol 2005; 175: 1329-36
48. Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003; 111: e622-7
49. Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003; 111: e622-7
50. Akman IO, Ostrov BE, Neudorf S. Autoimmune manifestations of the Wiskott-Aldrich syndrome. Semin Arthritis Rheum 1998; 27: 218-25
51. Shimizu M, Nikolov NP, Ueno K, et al. Development of IgA nephropathy-like glomerulonephritis associated with Wiskott-Aldrich syndrome protein deficiency. Clin Immunol 2012; 142: 160-6
52. Strom TS. The thrombocytopenia of WAS: a familial form of ITP? Immunol Res 2009; 44: 42-53
53. Semple JW, Siminovitch KA, Mody M, et al. Flow cytometric analysis of platelets from children with the Wiskott-Aldrich syndrome reveals defects in platelet development, activation and structure. Br J Haematol 1997; 97: 747-54
54. Pellier I, Dupuis GS, Loisel D, et al. Occurrence of aortic aneurysms in 5 cases of Wiskott-Aldrich syndrome. Pediatrics 2011; 127: e498-504
55. Tran H, Nourse J, Hall S, et al. Immunodeficiency-associated lymphomas. Blood Rev 2008; 22: 261-81
56. Yoshimi A, Kamachi Y, Imai K, et al. Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia. Pediatr Blood Cancer 2013; 60: 836-41
57. Sano H, Kobayashi R, Suzuki D, et al. Wiskott-Aldrich syndrome with unusual clinical features similar to juvenile myelomonocytic leukemia. Int J Hematol 2012; 96: 279-83
58. Ochs HD, Filipovich AH, Veys P, et al. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant 2009; 15: 84-90
59. Zhu Q, Watanabe C, Liu T, et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood 1997; 90: 2680-9
60. Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 2006; 108: 2182-9
61. Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001; 27: 313-17
62. Moulding DA, Moeendarbary E, Valon L, et al. Excess F-actin mechanically impedes mitosis leading to cytokinesis failure in X-linked neutropenia by exceeding Aurora B kinase error correction capacity. Blood 2012; 120: 3803-11
63. Kawai S, Minegishi M, Ohashi Y, et al. Flow cytometric determination of intracytoplasmic Wiskott-Aldrich syndrome protein in peripheral blood lymphocyte subpopulations. J Immunol Methods 2002; 260: 195-205
64. Yamada M, Ohtsu M, Kobayashi I, et al. Flow cytometric analysis of Wiskott-Aldrich syndrome (WAS) protein in lymphocytes from WAS patients and their familial carriers. Blood 1999; 93: 756-7
65. MacCarthy-Morrogh L, Gaspar HB, Wang YC, et al. Absence of expression of the Wiskott-Aldrich syndrome protein in peripheral blood cells of Wiskott-Aldrich syndrome patients. Clin Immunol Immunopathol 1998; 88: 22-7
66. Imai K, Nonoyama S, Ochs HD. WASP (Wiskott-Aldrich syndrome protein) gene mutations and phenotype. Curr Opin Allergy Clin Immunol 2003; 3: 427-36
67. Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood 2004; 104: 4010-19
68. Lanzi G, Moratto D, Vairo D, et al. A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. J Exp Med 2012; 209 (1): 29-34
69. Luthi JN, Gandhi MJ, Drachman JG. X-linked thrombocytopenia caused by a mutation in the Wiskott-Aldrich syndrome (WAS) gene that disrupts interaction with the WAS protein (WASP)-interacting protein (WIP). Exp Hematol 2003; 31: 150-8
70. Rong SB, Vihinen M. Structural basis of Wiskott-Aldrich syndrome causing mutations in the WH1 domain. J Mol Med 2000; 78: 530-7
71. Stewart DM, Tian L, Nelson DL. Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting protein. J Immunol 1999; 162: 5019-24
72. Volkman BF, Prehoda KE, Scott JA, et al. Structure of the N-WASP EVH1 domain-WIP complex: insight into the molecular basis of Wiskott-Aldrich Syndrome. Cell 2002; 111: 565-76
73. Worth AJ, Metelo J, Bouma G, et al. Disease-associated missense mutations in the EVH1 domain disrupt intrinsic WASp function causing dysregulated actin dynamics and impaired dendritic cell migration. Blood 2013; 121: 72-84
74. Greer WL, Shehabeldin A, Schulman J, et al. Identification of WASP mutations, mutation hotspots and genotype-phenotype disparities in 24 patients with the Wiskott-Aldrich syndrome. Hum Genet 1996; 98: 685-90
75. Buchbinder D, Nadeau K, Nugent D. Monozygotic twin pair showing discordant phenotype for X-linked thrombocytopenia and Wiskott-Aldrich syndrome: a role for epigenetics? J Clin Immunol 2011; 31: 773-7
76. Wengler G, Gorlin JB, Williamson JM, et al. Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. Blood 1995; 85: 2471-7
77. Boonyawat B, Dhanraj S, Al AF, et al. Combined de-novo mutation and non-random X-chromosome inactivation causing Wiskott-Aldrich syndrome in a female with thrombocytopenia. J Clin Immunol 2013; 33: 1150-5
78. Conley ME, Wang WC, Parolini O, et al. Atypical Wiskott-Aldrich syndrome in a girl. Blood 1992; 80: 1264-9
79. Lutskiy MI, Sasahara Y, Kenney DM, et al. Wiskott-Aldrich syndrome in a female. Blood 2002; 100: 2763-8
80. Parolini O, Ressmann G, Haas OA, et al. X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med 1998; 338: 291-5
81. Davis BR, Candotti F. Revertant somatic mosaicism in the Wiskott-Aldrich syndrome. Immunol Res 2009; 44: 127-31
82. Davis BR, Yan Q, Bui JH, et al. Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants. Clin Immunol 2010; 135: 72-83
83. Lutskiy MI, Park JY, Remold SK, et al. Evolution of highly polymorphic T cell populations in siblings with the Wiskott-Aldrich Syndrome. PLoS ONE 2008; 3: e3444
84. Trifari S, Scaramuzza S, Catucci M, et al. Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: analysis of function and distribution in lymphoid organs. J Allergy Clin Immunol 2010; 125: 439-48
85. Lutskiy MI, Beardsley DS, Rosen FS, Remold-ODonnell E. Mosaicism of NK cells in a patient with Wiskott-Aldrich syndrome. Blood 2005; 106: 2815-17
86. Gallego MD, Santamaria M, Pena J, Molina IJ. Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation. Blood 1997; 90: 3089-97
87. Vermi W, Blanzuoli L, Kraus MD, et al. The spleen in the Wiskott-Aldrich syndrome: histopathologic abnormalities of the white pulp correlate with the clinical phenotype of the disease. Am J Surg Pathol 1999; 23: 182-91
88. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156-63
89. Conley ME, Saragoussi D, Notarangelo L, et al. An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome. Clin Immunol 2003; 109: 272-7
90. Litzman J, Jones A, Hann I, et al. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome. Arch Dis Child 1996; 75: 436-9
91. Mathew P, Conley ME. Effect of intravenous gammaglobulin (IVIG) on the platelet count in patients with Wiskott-Aldrich syndrome. Pediatr Allergy Immunol 1995; 6: 91-4
92. Gerrits AJ, Leven E, Frelinger AL, et al. Effects of eltrombopag on thrombocytopenia, platelet function and bleeding in patients with wiskott-aldrich syndrome/x-linked thrombocytopenia. Am Soc Haematol 2013
93. Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011; 118: 1675-84
94. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008; 111: 439-45
95. Parkman R, Rappeport J, Geha R, et al. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. N Engl J Med 1978; 298: 921-7
96. Kapoor N, Kirkpatrick D, Blaese RM, et al. Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide. Blood 1981; 57: 692-6
97. Friedrich W, Schutz C, Schulz A, et al. Results and long-term outcome in 39 patients with Wiskott-Aldrich syndrome transplanted from HLA-matched and-mismatched donors. Immunol Res 2009; 44: 18-24
98. Kobayashi R, Ariga T, Nonoyama S, et al. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol 2006; 135: 362-6
99. Pai SY, DeMartiis D, Forino C, et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant 2006; 38: 671-9
100. Shin CR, Kim MO, Li D, et al. Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. Bone Marrow Transplant 2012; 47: 1428-35
101. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010; 126: 602-10
102. Mitchell R, Nivison-Smith I, Anazodo A, et al. Outcomes of hematopoietic stem cell transplantation in primary immunodeficiency: a report from the Australian and New Zealand Childrens Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. Biol Blood Marrow Transplant 2013; 19: 338-43
103. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003; 361: 553-60
104. Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the international bone marrow transplant registry and the national marrow donor program. Blood 2001; 97: 1598-603
105. Oshima K, Imai K, Albert MH, et al. Hematopoietic stem cell transplantation for X-linked thrombocytopenia with mutations in the WAS gene. J Clin Immunol 2014. [Epub ahead of print]
106. Morio T, Atsuta Y, Tomizawa D, et al. Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. Br J Haematol 2011; 154: 363-72
107. Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. Blood 2014; 124: 822-6
108. Locatelli F, Pende D, Mingari MC, et al. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol 2013; 4: 15
109. Kharya G, Nademi Z, Leahy TR, et al. Haploidentical T-cell alpha beta receptor and CD19-depleted stem cell transplant for Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2014; 134: 1199-201
110. Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105: 879-85
111. Chiesa R, Veys P. Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies. Expert Rev Clin Immunol 2012; 8: 255-66
112. Gungor T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014; 383: 436-48
113. Slatter MA, Rao K, Amrolia P, et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 2011; 117: 4367-75
114. Yamaguchi K, Ariga T, Yamada M, et al. Mixed chimera status of 12 patients with Wiskott-Aldrich syndrome (WAS) after hematopoietic stem cell transplantation: evaluation by flow cytometric analysis of intracellular WAS protein expression. Blood 2002; 100: 1208-14
115. Haines HL, Bleesing JJ, Davies SM, et al. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant 2015; 21: 288-92
116. Adriani M, Aoki J, Horai R, et al. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. Clin Immunol 2007; 124: 41-8
117. Humblet-Baron S, Sather B, Anover S, et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Investig 2007; 117: 407-18
118. Maillard MH, Cotta-de-Almeida V, Takeshima F, et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4+CD25+Foxp3+ regulatory T cells. The J Exper Med 2007; 204: 381-91
119. Astrakhan A, Ochs HD, Rawlings DJ. Wiskott-Aldrich syndrome protein is required for homeostasis and function of invariant NKT cells. J Immunol 2009; 182: 7370-80
120. Locci M, Draghici E, Marangoni F, et al. The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. J Exp Med 2009; 206: 735-42
121. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784-9
122. Kamani NR, Kumar S, Hassebroek A, et al. Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2011; 17: 1783-9
123. Worth A, Conyers R, Cohen J, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol 2011; 155: 377-85
124. Eapen M, Ahn KW, Orchard PJ, et al. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biol Blood Marrow Transplant 2012; 18: 1438-45
125. Boztug K, Dewey RA, Klein C. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther 2006; 8: 390-5
126. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity. Sci Transl Med 2014; 6: 227ra33
127. Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011; 3: 97ra79
128. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363: 355-64
129. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013; 341: 1233151
130. Hacein-Bey-Abina S, Gaspar HB, Blondeau J, et al. Clinical efficacy of gene therapy for severe wiskott-aldrich syndrome. JAMA 2015; 313 (15): 1550-63
131. Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010; 115: 3231-8
132. Sarkar K, Sadhukhan S, Han SS, Vyas YM. Disruption of hSWI/SNF complexes in T cells by WAS mutations distinguishes X-linked thrombocytopenia from Wiskott-Aldrich syndrome. Blood 2014; 124: 3409-19
133. Corash L, Shafer B, Blaese RM. Platelet-associated immunoglobulin, platelet size, and the effect of splenectomy in the Wiskott-Aldrich syndrome. Blood 1985; 65: 1439-43
134. Mullen CA, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. Blood 1993; 82: 2961-6
135. Pershin ES, Viktorova EA, Osipova EY, et al. Thrmobopoietin (TPO) receptor agonists romiplostim is effective in treatment of thrombocytopenia in Wiskott Aldrich Syndrome. 16th Biennial meeting of the European Society of Immunodefiencies, Prague, 2014
136. Massaad MJ, Ramesh N, Le BS, et al. A peptide derived from the Wiskott-Aldrich syndrome (WAS) protein-interacting protein (WIP) restores WAS protein level and actin cytoskeleton reorganization in lymphocytes from patients with WAS mutations that disrupt WIP binding. J Allergy Clin Immunol 2011; 127: 998-1005
137. Kahraman S, Beyazyurek C, Yesilipek MA, et al. Successful haematopoietic stem cell transplantation in 44 children from healthy siblings conceived after preimplantation HLA matching. Reprod Biomed Online 2014; 29: 340-51
138. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006; 117: 725-38